PF-07923567
/ Pfizer
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
October 21, 2024
Safety, Pharmacokinetics,and Antiviral Activity of RV299 Against Respiratory Syncytical Virus (RSV)
(clinicaltrials.gov)
- P1 | N=82 | Completed | Sponsor: Pfizer | Phase classification: P1b ➔ P1
Phase classification • Respiratory Diseases
October 04, 2023
Safety, Pharmacokinetics,and Antiviral Activity of RV299 Against Respiratory Syncytical Virus (RSV)
(clinicaltrials.gov)
- P1b | N=82 | Completed | Sponsor: Pfizer
New P1 trial • Respiratory Diseases
1 to 2
Of
2
Go to page
1